2021 Dihydroorotate Dehydrogenase Inhibitors Pipeline Market Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dihydroorotate Dehydrogenase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Dihydroorotate dehydrogenase inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate dehydrogenase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dihydroorotate dehydrogenase inhibitors R&D. The therapies under development are focused on novel approaches for Dihydroorotate dehydrogenase inhibitors.

Dihydroorotate dehydrogenase inhibitors Emerging Drugs Chapters

This segment of the Dihydroorotate dehydrogenase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dihydroorotate dehydrogenase inhibitors Emerging Drugs

IMU-838: Immunic

IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.

PTC 299: PTC Therapeutics

Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.

Dihydroorotate dehydrogenase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Dihydroorotate dehydrogenase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Dihydroorotate dehydrogenase inhibitors

There are approx. 10+ key companies which are developing the Dihydroorotate dehydrogenase inhibitors. The companies which have their Dihydroorotate dehydrogenase inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, Immunic

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Dihydroorotate dehydrogenase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dihydroorotate dehydrogenase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate dehydrogenase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate dehydrogenase inhibitors drugs.

Dihydroorotate dehydrogenase inhibitors Report Insights

• Dihydroorotate dehydrogenase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dihydroorotate dehydrogenase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Dihydroorotate dehydrogenase inhibitors drugs?
• How many Dihydroorotate dehydrogenase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Dihydroorotate dehydrogenase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dihydroorotate dehydrogenase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dihydroorotate dehydrogenase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanofi
• Immunic
• PTC Therapeutics
• Clear Creek Bio
• EyeGate Pharma
• ASLAN Pharmaceuticals
• Medicines for Malaria Venture

Key Products

• Teriflunomide
• IMU-838
• Emvododstat
• Olorofim
• Brequinar
• PP 001 EyeGate Pharma
• ASLAN-003
• MMV-1793609

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a81zd4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900